« Previous
Next »
Titles
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Estimated changes to employer-sponsored health insurance premiums due to the drug inflation rebate provision of the Build Back Better Act1
- Examining two approaches to U.S. drug pricing: international prices and therapeutic equivalency1
- Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries1
